Humacyte
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Humacyte sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Humacyte: 6 sponsored US clinical trials, 1 recruiting.
Humacyte sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Vascular System Injury, with 1 trials.
Upper-quartile sponsor footprint
Humacyte sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084
Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
NCT03005418
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
NCT03183245
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
NCT02887859
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
NCT02644941
Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
NCT01840956
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Humacyte pipeline
1 recruiting of 6 indexed (17% open); 4 completed (67%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Vascular System Injury (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Humacyte: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Humacyte sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Humacyte page
6 registered trials is a research-attention snapshot, not an endorsement of Humacyte or any single study.
- 1 of Humacyte's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Vascular System Injury is the condition Humacyte studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Vascular System Injury trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Humacyte pipeline card: 6 registered trials from official public datasets.Report a data error.